FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

STAT Plus: FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Some thoughts, analysis, and lingering questions for investors trying to figure out what the FDA's decision on the company's Duchenne drug is all about.

READ MORE